ProCE Banner Activity

MK-8591A-051: Phase III Trial of Switch From Standard-of-Care ART to DOR/ISL in People Living With Virologically Suppressed HIV

Conference Coverage
Slideset

Results from the phase III MK-8591A-051 trial demonstrate that switching to DOR/ISL is noninferior to continuing standard-of-care ART in people living with virologically suppressed HIV, with no impact on total lymphocyte or CD4+ cell counts.

Released: March 13, 2025

Expiration: September 12, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from Gilead Sciences, Inc., Merck & Co., Inc., Rahway, NJ, USA, and ViiV Healthcare.

Gilead Sciences, Inc.

Merck & Co., Inc., Rahway, NJ, USA

ViiV Healthcare